209 related articles for article (PubMed ID: 27784441)
21. Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?
Wege H; Brümmendorf TH
Curr Stem Cell Res Ther; 2007 Jan; 2(1):31-8. PubMed ID: 18220890
[TBL] [Abstract][Full Text] [Related]
22. [Telomeres and telomerase].
Dahse R; Fiedler W; Ernst G
Pathologe; 1997 Nov; 18(6):425-9. PubMed ID: 9451730
[TBL] [Abstract][Full Text] [Related]
23. Cellular functions of the dual-targeted catalytic subunit of telomerase, telomerase reverse transcriptase--potential role in senescence and aging.
Ale-Agha N; Dyballa-Rukes N; Jakob S; Altschmied J; Haendeler J
Exp Gerontol; 2014 Aug; 56():189-93. PubMed ID: 24583100
[TBL] [Abstract][Full Text] [Related]
24. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential.
Wege H; Le HT; Chui MS; Liu L; Wu J; Giri R; Malhi H; Sappal BS; Kumaran V; Gupta S; Zern MA
Gastroenterology; 2003 Feb; 124(2):432-44. PubMed ID: 12557149
[TBL] [Abstract][Full Text] [Related]
25. Ageing and cancer: the telomere and telomerase connection.
Shay JW; Wright WE
Novartis Found Symp; 2001; 235():116-25; discussion 125-9, 146-9. PubMed ID: 11280022
[TBL] [Abstract][Full Text] [Related]
26. Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.
Maida Y; Masutomi K
Cancer Sci; 2015 Nov; 106(11):1486-92. PubMed ID: 26331588
[TBL] [Abstract][Full Text] [Related]
27. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
28. [Abnormality of telomere maintenance linked to bone marrow failures].
Yamaguchi H
Nihon Rinsho; 2008 Mar; 66(3):483-9. PubMed ID: 18326318
[TBL] [Abstract][Full Text] [Related]
29. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
30. Telomere length homeostasis.
Hug N; Lingner J
Chromosoma; 2006 Dec; 115(6):413-25. PubMed ID: 16741708
[TBL] [Abstract][Full Text] [Related]
31. Hallmarks of telomeres in ageing research.
Shay JW; Wright WE
J Pathol; 2007 Jan; 211(2):114-23. PubMed ID: 17200948
[TBL] [Abstract][Full Text] [Related]
32. Telomerase and cancer.
Shay JW; Zou Y; Hiyama E; Wright WE
Hum Mol Genet; 2001 Apr; 10(7):677-85. PubMed ID: 11257099
[TBL] [Abstract][Full Text] [Related]
33. Revisiting Telomere Shortening in Cancer.
Okamoto K; Seimiya H
Cells; 2019 Jan; 8(2):. PubMed ID: 30709063
[TBL] [Abstract][Full Text] [Related]
34. Regulation of telomere length and homeostasis by telomerase enzyme processivity.
D'Souza Y; Lauzon C; Chu TW; Autexier C
J Cell Sci; 2013 Jan; 126(Pt 2):676-87. PubMed ID: 23178942
[TBL] [Abstract][Full Text] [Related]
35. Introduction to Telomeres and Telomerase.
Songyang Z
Methods Mol Biol; 2017; 1587():1-13. PubMed ID: 28324493
[TBL] [Abstract][Full Text] [Related]
36. Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome.
Du HY; Idol R; Robledo S; Ivanovich J; An P; Londono-Vallejo A; Wilson DB; Mason PJ; Bessler M
Aging Cell; 2007 Oct; 6(5):689-97. PubMed ID: 17875000
[TBL] [Abstract][Full Text] [Related]
37. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
38. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.
Wang L; Xiao H; Zhang X; Wang C; Huang H
J Hematol Oncol; 2014 Aug; 7():61. PubMed ID: 25139287
[TBL] [Abstract][Full Text] [Related]
39. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data.
Tornesello ML; Tornesello AL; Starita N; Cerasuolo A; Izzo F; Buonaguro L; Buonaguro FM
Expert Opin Ther Targets; 2022 Sep; 26(9):767-780. PubMed ID: 36369706
[TBL] [Abstract][Full Text] [Related]
40. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease.
Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL
Gastroenterology; 2007 Apr; 132(4):1465-75. PubMed ID: 17433324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
